ProQR's QR-421a Receives FDA's Rare Pediatric Disease Designation for Retinitis Pigmentosa
Shots:
- The US FDA has granted RPD to the QR-421a for the treatment of patients with retinitis pigmentosa caused by mutations in exon 13 of the USH2A gene
- The RPD designation provides PR voucher by the FDA to the sponsor- that voucher can be redeemed to receive FDA’s PR designation for any subsequent MAA for a different product
- QR-421a (IVT) is a first-in-class investigational RNA-based oligonucleotide addressing the underlying cause of vision loss in Usher syndrome type 2 and non-syndromic RP due to mutations in exon 13 of the USH2A gene and has received FDA’s ODD and EU’s FT designation
Click here to read full press release/ article | Ref: ProQR | Image: ProQR
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com